SLC6A3 and Parkinson disease: A number of factors have been identified to be associated with FOG in PD patients, including disease duration, motor phenotypes, CSVD neuroimaging markers, cerebrospinal fluid β-amyloid 42 (Aβ42), dopamine transporter (DAT) uptake, and cognitive impairment (20–22).